Gastroesophageal Junction Cancer Latest Advances
Find the Latest Research About Gastroesophageal Junction Cancer
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1192 publications
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
A Case of Recurrent Esophagogastric Junction Cancer with Long‒Term Complete Response by Trastuzumab Deruxtecan
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: May 25, 2026
Construction of a predictive model for the efficacy of immune checkpoint inhibitors in locally advanced or metastatic gastric cancer and esophagogastric junction cancer
Journal: Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Published: May 20, 2026
Zolbetuximab: research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18.2.
Journal: Recenti progressi in medicina
Published: May 07, 2026
A Case of Esophagogastric Junction Cancer Treated with Perioperative Nivolumab Therapy
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: May 07, 2026
Promising New Platforms and Targets in the Management of Gastroesophageal Cancers.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 07, 2026
Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 05, 2026
UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA).
Journal: ESMO gastrointestinal oncology
Published: April 30, 2026
Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-positive advanced or metastatic gastric or gastroesophageal cancer: a meta-analysis of single-arm trials.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: April 23, 2026
Testing Claudin 18.2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma: Current Status and Near‑Future Outlook.
Journal: Ceskoslovenska patologie
Published: April 17, 2026
DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer.
Journal: ESMO gastrointestinal oncology
Published: April 17, 2026
Last Updated: 06/30/2026